S. Poulain

发表

Obinutuzumab and idelalisib in symptomatic patients with relapsed/refractory Waldenström macroglobulinemia.

O. Casasnovas, S. Leprêtre, S. Chevret, 2021, Blood advances.

Laboratory Investigations and Findings: Hematological Abnormalities, Biochemical Investigations, Free Light and Heavy Chains

E. Bertrand, I. Ghobrial, X. Leleu, 2017 .

BACH2 promotes indolent clinical presentation in Waldenström macroglobulinemia

B. Quesnel, E. Bertrand, C. Preudhomme, 2016, Oncotarget.

Increased trisomy 12 frequency and a biased IgVH 3-21 gene usage characterize small lymphocytic lymphoma.

C. Bastard, P. Morel, P. Duthilleul, 2010, Leukemia research.

Shared clonal IGH rearrangement in BCP‐ALL occurring after CLL: pitfalls and implications for MRD monitoring

C. Preudhomme, J. Marolleau, N. Grardel, 2020, British journal of haematology.

BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia.

F. Lemonnier, P. Staber, M. Davids, 2021, Blood.

High frequency of clonal hematopoiesis in Erdheim-Chester disease.

O. Abdel-Wahab, O. Bernard, J. Emile, 2020, Blood.

Clinical relevance of soluble HLA class I molecules in Waldenstrom Macroglobulinemia

A. Duhamel, S. Treon, A. Roccaro, 2008, European journal of haematology.

Clinical and biological characteristics of leukemia cutis in chronic lymphocytic leukemia: A study of the French innovative leukemia organization (FILO)

P. Feugier, J. Vial, S. Leprêtre, 2021, American journal of hematology.

The IL6(-174G/C) polymorphism is a prognostic factor for survival after treatment initiation in Waldenström macroglobulinemia patients aged 65 years or less

I. Dervite, P. Morel, X. Leleu, 2008, Haematologica.

Absence of CXCR4 mutations but high incidence of double mutant in CD79A/B and MYD88 in primary central nervous system lymphoma

C. Preudhomme, C. Maurage, S. Tricot, 2015, British journal of haematology.

Genome wide SNP array identified multiple mechanisms of genetic changes in Waldenstrom macroglobulinemia

B. Quesnel, E. Bertrand, C. Preudhomme, 2013, American journal of hematology.

Working Toward a Genomic Prognostic Classification of Waldenström Macroglobulinemia: C-X-C Chemokine Receptor Type 4 Mutation and Beyond.

X. Leleu, C. Tomowiak, S. Poulain, 2018, Hematology/oncology clinics of North America.

Expression of lung resistance protein and correlation with other drug resistance proteins and outcome in myelodysplastic syndromes.

C. Preudhomme, P. Fenaux, N. Grardel, 1998, Leukemia & lymphoma.

Continuous MYD88 Activation Is Associated With Expansion and Then Transformation of IgM Differentiating Plasma Cells

I. Soubeyran, M. Espéli, C. Carrion, 2021, Frontiers in Immunology.

Rationale for the combination of venetoclax and ibrutinib in T-prolymphocytic leukemia

C. Guillemette, U. Jäger, P. Staber, 2021, Haematologica.

Role of IRF4 in resistance to immunomodulatory (IMid) compounds® in Waldenström’s macroglobulinemia

B. Quesnel, E. Bertrand, C. Preudhomme, 2017, Oncotarget.

High-throughput genomic analysis in Waldenström's macroglobulinemia.

R. Fonseca, E. Braggio, X. Leleu, 2011, Clinical lymphoma, myeloma & leukemia.

99 Expression of LRP and its correlation with other drug resistance proteins and outcome in myelodysplastic syndromes (MDS)

E. Wattel, C. Preudhomme, P. Fenaux, 1997 .

How Recent Advances in Biology of Waldenström’s Macroglobulinemia May Affect Therapy Strategy

V. Leblond, S. Poulain, L. Simon, 2019, Current Oncology Reports.

LYMPHOID NEOPLASIA MYD88 L265P mutation in Waldenstrom macroglobulinemia

E. Bertrand, S. Tricot, Aline Renneville, 2013 .

Germline PAX5 mutation predisposes to familial B acute lymphoblastic leukemia.

C. Preudhomme, Aurélie Caillault, C. Berthon, 2020, Blood.

Is ZAP-70 expression stable over time in B chronic lymphocytic leukaemia?

P. Morel, P. Duthilleul, S. Poulain, 2007, Leukemia & lymphoma.

Next-CLL: a new next generation sequencing-based method for assessment of IGHV gene mutational status in chronic lymphoid leukemia.

S. Hayette, E. Ferrant, P. Sujobert, 2023, The Journal of molecular diagnostics : JMD.

Efficacy of ibrutinib in the treatment of Bing–Neel syndrome

J. Bay, O. Tournilhac, S. Mourah, 2016, American journal of hematology.

MYD88 L265P mutation in Waldenstrom macroglobulinemia.

B. Quesnel, E. Bertrand, C. Preudhomme, 2012, Blood.

Guideline for the diagnosis, treatment and response criteria for Bing-Neel syndrome

M. Kersten, E. Kimby, M. Dimopoulos, 2017, Haematologica.

Novel M-component based biomarkers in Waldenström's macroglobulinemia.

I. Ghobrial, X. Leleu, M. Kyrtsonis, 2011, Clinical lymphoma, myeloma & leukemia.

CD3−CD4+ lymphoid variant of hypereosinophilic syndrome: nodal and extranodal histopathological and immunophenotypic features of a peripheral indolent clonal T-cell lymphoproliferative disorder

G. Salles, M. Copin, C. Preudhomme, 2015, Haematologica.

Amplification of BCR-ABL rearrangement in atypical Philadelphia chromosome: a new variant detected by fluorescence in situ hybridization in one case of acute lymphoblastic leukemia.

M. Simon, P. Duthilleul, S. Poulain, 1999, Cancer genetics and cytogenetics.

Expression of the multidrug resistance‐associated protein in myelodysplastic syndromes

E. Wattel, C. Preudhomme, P. Fenaux, 2000, British journal of haematology.

Assessment of P-glycoprotein expression by immunocytochemistry and flow cytometry using two different monoclonal antibodies coupled with functional efflux analysis in 34 patients with acute myeloid leukemia.

E. Wattel, P. Fenaux, A. Cosson, 1999, Advances in experimental medicine and biology.

SDF1/CXCL12 (-801GA) polymorphism is a prognostic factor after treatment initiation in Waldenstrom macroglobulinemia.

P. Morel, X. Leleu, V. Coiteux, 2009, Leukemia research.

Update on therapeutic options in Waldenström macroglobulinemia

I. Ghobrial, X. Leleu, A. Moreau, 2009, European journal of haematology.

Lenalidomide is safe and active in Waldenström macroglobulinemia

G. Salles, P. Morel, X. Leleu, 2015, American journal of hematology.

Low expression of pro-apoptotic Bcl-2 family proteins sets the apoptotic threshold in Waldenström Macroglobulinemia

S. Lonial, A. Chanan-Khan, J. Kowalski, 2015, Oncogene.

Genomic studies have identified multiple mechanisms of genetic changes in Waldenström macroglobulinemia.

E. Bertrand, X. Leleu, C. Roumier, 2013, Clinical lymphoma, myeloma & leukemia.

Recommendations for the diagnosis and initial evaluation of patients with Waldenström Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenström Macroglobulinaemia

M. Dimopoulos, R. Kyle, S. Treon, 2016, British journal of haematology.

MYD88 L265P mutation contributes to the diagnosis of Bing Neel syndrome

B. Quesnel, E. Bertrand, C. Preudhomme, 2014, British journal of haematology.

Diagnostics in Waldenström’s macroglobulinemia: a consensus statement of the European Consortium for Waldenström’s Macroglobulinemia

M. Kersten, C. Buske, N. Puig, 2022, Leukemia.

The bendamustine plus rituximab regimen is active against primary nodal marginal zone B‐cell lymphoma

K. Laribi, Anne Besançon, S. Poulain, 2017, Hematological oncology.

Balancing risk versus benefit in the treatment of Waldenström's Macroglobulinemia patients with nucleoside analogue-based therapy.

J. Tamburini, P. Morel, S. Treon, 2009, Clinical lymphoma & myeloma.

Successful and safe response to ibrutinib alone in treating relapsed Waldenström macrogobulinemia and related acquired von Willebrand syndrome: an option to consider

S. Susen, A. Bauters, A. Dupont, 2022, Leukemia & lymphoma.

Bendamustine plus rituximab in newly‐diagnosed Waldenström macroglobulinaemia patients. A study on behalf of the French Innovative Leukaemia Organization (FILO)

M. Béné, K. Laribi, V. Leblond, 2018, British journal of haematology.

TP53 Mutation and Its Prognostic Significance in Waldenstrom's Macroglobulinemia

B. Quesnel, E. Bertrand, C. Preudhomme, 2017, Clinical Cancer Research.

Open Label Non-Randomized Phase II Study Exploring «Chemo-Free » Treatment Association with Idelalisib + Obinutuzumab in Patients with Relapsed/Refractory (R/R) Waldenstrom's Macroglobulinemia (MW), a Filo Trial: Results of the Intermediary Analysis of the Induction Phase

O. Casasnovas, S. Leprêtre, S. Chevret, 2019, Blood.

The Bendamustine Plus Rituximab Regimen Is Active and Safe in Previously Untreated Patients with Waldenström Macroglobulinemia, a Study on Behalf of the French Innovative Leukemia Organization (FILO)

M. Béné, K. Laribi, V. Leblond, 2017 .

Mast cell density and its clinical relevance in Waldenström's macroglobulinemia

C. Godfraind, F. Davi, J. Bay, 2017, EJHaem.

TCL1 expression patterns in Waldenström macroglobulinemia

P. Morel, X. Leleu, J. Bay, 2016, Modern Pathology.

Hevylite, a Novel M-Component Based Biomarkers of Response to Therapy and Survival in Waldenstrom Macroglobulinemia

X. Leleu, V. Leblond, L. Musset, 2011 .

Daratumumab and dexamethasone is safe and effective for triple refractory myeloma patients: final results of the IFM 2014‐04 (Etoile du Nord) trial

M. Mohty, P. Moreau, H. Avet-Loiseau, 2019, British journal of haematology.

Autoimmune hemolytic anemias and IgG antierythrocyte autoantibodies in Waldenström's macroglobulinemia: association with FcγRIIa polymorphism

I. Dervite, P. Morel, X. Leleu, 2006, Leukemia.

[Waldenström's macroglobulinemia].

P. Morel, X. Leleu, B. Hivert, 2010, La Revue de medecine interne.

Comparison of Waldenstrom Macroglobulinemia Responses Using Immunoglobulin Heavy / Light Chain Analysis and Conventional Electrophoresis Techniques

X. Leleu, V. Leblond, L. Musset, 2014 .

Report of Consensus Panel 3 from the 11th International workshop on Waldenström's Macroglobulinemia: Recommendations for molecular diagnosis in Waldenström's Macroglobulinemia.

Lin Qiu, M. Leiba, R. García-Sanz, 2023, Seminars in hematology.

The Broad Spectrum of TP53 Mutations in CLL: Evidence of Multiclonality and Novel Mutation Hotspots

A. Ameur, R. Letestu, T. Soussi, 2023, Human Mutation.

TP53 mutations at codon 234 are associated with chlorambucil treatment in chronic lymphocytic leukemia

R. Letestu, T. Soussi, F. Baran-Marszak, 2022, American journal of hematology.

JAK2 V617F mutation is absent in chronic lymphocytic leukemia

P. Morel, M. Simon, P. Duthilleul, 2006, Leukemia & lymphoma.

Kinetic of chronic myeloid leukaemia (CML) prevalence in Northern France since the introduction of imatinib

C. Preudhomme, T. Facon, J. Laï, 2008 .

TOP3A, a new partner gene fused to MLL in an adult patient with de novo acute myeloid leukaemia

R. Marschalek, C. Meyer, S. Tricot, 2012, British Journal of Haematology.

Genome Wide SNP Analysis Reveals Frequent Cryptic Clonal Chromosomal Aberrations Including Uniparental Disomy (UPD) in Waldenstrom's Macroglobulinemia.

C. Preudhomme, P. Morel, X. Leleu, 2009 .

New developments in the diagnosis and characterization of Waldenström’s macroglobulinemia

Z. Hunter, M. Varettoni, S. Poulain, 2023, Expert review of hematology.